Gliadel in glioblastoma: Is there a need for defining placement conditions?

Jan Küchler, Volker Tronnier & Mattheo Bonsanto
Objective: Placement of carmustin wafers (Gliadel) as a local chemotherapeutic depot has become a common practice in glioblastoma (GBM) resection. Different studies have reported a survival benefit, but the results vary widely. Those studies include a lot of clinical parameters but do not define the[for full text, please go to the a.m. URL]